Company Encyclopedia
View More
name
AIM IMMUNOTECH INC
AIMID.US
1.902 T
AIMID.USMarket value -Rank by Market Cap -/-

Financial Score

14/12/2025 Update
E
BiotechnologyIndustry
Industry Ranking392/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-10862.86%E
    • Profit Margin-10416.44%E
    • Gross Margin37.50%B
  • Growth ScoreD
    • Revenue YoY-24.35%E
    • Net Profit YoY51.13%B
    • Total Assets YoY-61.41%E
    • Net Assets YoY-179.92%E
  • Cash ScoreD
    • Cash Flow Margin-0.96%D
    • OCF YoY-24.35%E
  • Operating ScoreE
    • Turnover0.01E
  • Debt ScoreE
    • Gearing Ratio161.73%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Aim Immunotech Reports Third Quarter 2025 Financial Results And Highlights Continued Progress Across Pipeline With Strategic Focus On Pancreatic Cancer Clinical Program

    AIM ImmunoTech Inc (AIM.A) :* AIM IMMUNOTECH REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND HIGHLIGHTS CONTINUED PROGRESS ACROSS PIPELINE WITH STRATEGIC FOCUS ON PANCREATIC CANCER CLINICAL PROGRAM Source text: Further company coverage: (AIM.A)

    Reuters·
    US
    AIM
    -5.52%
    US
    AIMID
    0.00%
    Reuters·
    US
    AIM
    -5.52%
    US
    AIMID
    0.00%

    AIM ImmunoTech Reports Q3 2025 Financial Results

    AIM ImmunoTech Inc. reported a Q3 2025 net loss of $3.3 million, improved from $3.7 million last year. Revenues decreased to $26,000 from $35,000. Total liabilities rose to $11.6 million from $9.9 million. Operating expenses dropped significantly, with R&D costs at $607,000 and administrative expenses at $1.8 million. Cash reserves increased to $2.3 million. AIM focuses on advancing clinical trials and improving financial sustainability amid regulatory challenges.

    Tip Ranks·
    US
    AIM
    -5.52%
    US
    AIMID
    0.00%
    Tip Ranks·
    US
    AIM
    -5.52%
    US
    AIMID
    0.00%

    AIM ImmunoTech Inc. SEC 10-Q Report

    AIM ImmunoTech Inc. released its Q3 2025 10-Q report, highlighting a decrease in total revenues to $26K for the quarter and $67K for nine months, compared to 2024. The company reported reduced operating and net losses. AIM focuses on developing Ampligen for cancer and viral treatments, with ongoing clinical trials and efforts to gain approval in Argentina. The company plans to continue R&D and seek collaborative grants. Ampligen is approved in Argentina for CFS, but economic conditions affect its market viability.

    TradingView·
    US
    AIMID
    0.00%
    US
    AIM
    -5.52%
    TradingView·
    US
    AIMID
    0.00%
    US
    AIM
    -5.52%

    AIM ImmunoTech Delays Quarterly Financial Report

    AIM ImmunoTech Inc. has delayed filing its quarterly financial report for the period ending September 30, 2025, and has notified the SEC of this late filing. The company anticipates a significant decrease in revenues for the quarter. This information was disclosed via the SEC's EDGAR system.

    Reuters·
    US
    AIMID
    0.00%
    US
    AIM
    -5.52%
    Reuters·
    US
    AIMID
    0.00%
    US
    AIM
    -5.52%

    Tencent: Not playing heartbeats with Meta, just seeking stable happiness

    After the Hong Kong stock market closed on November 13, Beijing time, $TENCENT(00700.HK) released its third-quarter 2025 results. Overall, while there were not many surprises compared to expectations, stability remains the key theme, with no significant weaknesses in the three major business lines. Since the beginning of this year, Tencent has entered a new investment cycle, yet traces of the management's refined operations and effective capital allocation can still be observed. Specifically: 1. Gaming remains the standout: Tencent Games maintained high growth of 23% in the third quarter, driven by the product cycle. Overseas, under the leadership of Supercell's 'Clash Royale,' it continued to surge (with favorable exchange rate contributions)...

    HK
    00700
    +2.41%
    US
    META
    -1.30%
    US
    SBC
    +1.46%
    HK
    00700
    +2.41%
    US
    META
    -1.30%
    US
    SBC
    +1.46%
    Posts
    View More
    © 2025 Longbridge｜Disclaimer